There are approximately 8 million stroke survivors in the U.S. with an estimated 795,000 strokes occurring each year. In addition, it is estimated that 1.5 million people suffer some sort of traumatic brain injury (TBI) annually. Among survivors of stroke and TBI, up to approximately 30 percent suffer a resultant visual impairment, up to 20 percent permanently.

(Sahraie, Romano)

Even partial blindness has a dramatic effect on people’s ability to live their daily lives, preventing them from working, driving, reading, shopping, crossing a road or staying home alone without help. Experts explain how computer-based, non-invasive therapies are making a meaningful, positive impact on the quality of life for these people.

(Sahraie, Romano)

An expert explains the concept and process of neuroplasticity, what distinguishes neurological vision loss from other kinds of blindness, and how advances in brain and vision sciences are helping patients restore lost vision.

(Pascual-Leone)

NovaVision’s VRT is a patient-specific therapy which is carefully monitored and modified on a monthly basis for each patient and is not to be confused with one-size-fits-all apps. An expert explains the importance of controlled intervention and the inherent danger of an unsupervised app.

(Pascual-Leone)

NovaVision’s VRT is based on 15 years of clinical research and over 20 studies. These showed that more than 70 percent of patients who used the therapy experience an increase in their visual field. Experts explain the science behind the first FDA-cleared therapy to help people with neurologically induced vision loss.

(Sahraie, Romano)

NovaVision’s VRT is a patient-specific, doctor-prescribed therapy delivered over a computer to the patient's home. It’s designed to identify a patient’s visual field deficit and provide customized therapy to improve vision via light-based stimuli. Experts explain how programmed light sequences stimulate the border zone between the “seeing” and “blind” visual fields, repetitively challenging the visual cortex with thousands of stimuli over the course of the therapy.

(Sahraie, Romano)

While NovaVision’s VRT addresses the restoration of lost vision, NovaVision’s NeuroEyeCoach is designed to address patients' difficulty with their eye movements, their ability to integrate visual information and enables them to make the most of their remaining vision. An expert explains how these two therapies address different aspects of visual impairments resulting from neurological damage, how they are complementary, and how in a therapy suite they deliver broad benefits to patients.

(Sahraie)

NeuroEyeCoach™ re-trains the ability of a patient to move their eyes, re-integrate left and right vision and make the most of their remaining visual field. It is based on decades of scientific research and was developed by Dr. Josef Zihl, a world leader in the field and NovaVision’s Chief Scientific Advisor. Dr Zihl explains how NeuroEyeCoach works.

(Zihl)

NovaVision is completing the migration of VRT from provided-hardware to internet-delivered onto patients' computers and streamlining business processes, thereby significantly reducing cost. Management explains how this will make NovaVision's therapies more affordable, and with broader benefits therefore providing a solution that is attractive and truly scalable and deliverable to the mass market.

(Zachariou, Cantor)